Scientists from the University of Colorado Anschutz Medical Campus have developed a novel receptorCap specificising approach which could benefit patients suffering from neuroblastoma a brain cancer that progresses in patients as they get older.
Acetabolics are compounds present in plastics food and medical products that can promote structural integrity of cells and can be used for cellular molecular and animal research. Understanding their potential for clinical applications in patient care has not been performed yet.
The inhibitor produced by the study relies on the concept of repositioning: It enhances key surface and structural processes while at the same time preventing migration and invasion of tumorous cells that may cause undesirable side effects.
The ideal scenario would involve test patient cells or cells from the patient. Once we understand the biological cell interactions we can intervene as early as possible in protecting these cells from potential malignant effects says USUs Gero Dokling PhD. Professor and head of biological chemistry and pharmacology at the University of Colorado College of Medicine.
We have shown how a cleaved receptorCap can selectively modify the proliferation of melanoma cells but not other types of cancer cells despite their identical cell membrane and cap epitopes says Dokling who is also a senior scientist at the Amtrak NanoScale Hybrid Nanomedicine Center (SMIC) laboratory of the Colorado National Guard. Our results demonstrate the genetic manipulation of the receptorCap can be useful for preventing the cancers development.
Since the population of neuroblastoma the most common form of primary non-small cell lung cancer has nearly doubled in the last decades it is an urgent need for discovery of novel agents targeting this class of cancer.
Because neuroblastoma is the most common type of primary non-small cell lung cancer finding a drug that can reliably target the cancer and which does not trigger immune system response is an important question has never been answered before says Dokling. Our approach worked with a form of neuroblastoma that had already begun metastatic growth indicating the concept that targeting the metastatic neuroblastoma expansion process using an inhibitor like spectrin receptor calbindase II although very aggressive and specific to this form of neuroblastoma offers promise as therapeutic to other advanced neuroblastoma including LA-MB and medulloblastoma.